UNSPSC 51351528: Pregnenolone sulfate

This classification denotes a therapeutic progestin with the molecular formula C21H32O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04Y4D91RG0, chemically known as pregn-5-en-20-one, 3-(sulfooxy)-, (3.beta.)-, but more generally known as pregnenolone sulfate, which bears US NIH Compound Identifier 105074. European Medicines Agency schedules pregnenolone sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG.

Most nations, for tariff purposes, schedule pregnenolone sulfate under HS 29372900. SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)C.

UNSPSC 51351528 Pregnenolone sulfate is a Commodity code representing pharmaceutical active ingredients and precursor compounds procured by state and local health systems, correctional facilities, and cooperative purchasing alliances. The code captures generic and brand-name pharmaceutical substances sourced through established wholesaler networks and pharmaceutical supply chains serving state and local government facilities. State and local buyers under this code typically operate through multistate cooperative purchasing vehicles that aggregate demand across multiple jurisdictions to achieve volume discounts and standardized pricing for pharmaceutical inventories.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The procurement spans participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation weights price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance criteria including EDI capability, administrative fee adherence, and data format compliance at 5 percent each. Vendors must hold current Good Manufacturing Practice certification, comply with the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, and carry commercial general liability insurance of $5 million per occurrence. Contract terms run two years for new responders with optional extensions, and all products must possess FDA compliance and at least one year expiration dates from manufacture.